DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Quetiapine on Marijuana Withdrawal and Relapse

Information source: New York State Psychiatric Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Marijuana Smoking

Intervention: Marijuana (Drug); Quetiapine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: New York State Psychiatric Institute

Official(s) and/or principal investigator(s):
Margaret Haney, Ph.D, Principal Investigator, Affiliation: New York State Psychiatric Institute


The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome. It is hypothesized that quetiapine will decrease marijuana withdrawal and relapse. Primary outcome measures will be 1. marijuana's direct effects 2. marijuana withdrawal syndromes 3. marijuana relapse. It is also hypothesized that marijuana withdrawal will be associated with increased levels of stress hormones. A secondary measure will be salivary cortisol.

Clinical Details

Official title: Effect of Quetiapine on Marijuana Withdrawal and Relapse

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Primary outcome: Marijuana relapse

Secondary outcome: Marijuana Withdrawal

Detailed description: Quetiapine improves sleep and reduces anxiety and irritability, which are symptoms of marijuana withdrawal. Further, there are case reports showing that marijuana-dependent schizophrenics maintained on quetiapine had a 97. 3% reduction in marijuana use. Thus, the purpose of this study is to determine if quetiapine decreases marijuana's direct effects, symptoms of marijuana withdrawal and marijuana relapse in the laboratory. The study will utilize and inpatient/outpatient, counter-balanced design, with each participant maintained on placebo and quetiapine (200 mg/day) for 18 days. Participants will begin taking capsules as outpatients so that the dose can be incremented prior to the inpatient phase. While inpatient, participants will have the opportunity to self-administer placebo or active marijuana 6 times per day. Our laboratory model, which has distinguished the effects of a range of medications on marijuana withdrawal and relapse, will provide important information on the effect of quetiapine as a potential short-term pharmacotherapy to facilitate abstinence in the initial stages of marijuana treatment.


Minimum age: 21 Years. Maximum age: 45 Years. Gender(s): Both.


Inclusion Criteria:

- Current marijuana use: average of 2 marijuana cigarettes per day at least 4 times per

week for the past 4 weeks

- Able to perform study procedures

- 21-45 years of age

- Women practicing an effective form of birth control (condoms, diaphragm, birth

control, pill, IUD)

- Normal body weight

Exclusion Criteria:

- Current, repeated illicit drug use (other than marijuana)

- Presence of significant medical illness (e. g., diabetes, cardiovascular disease,

hypertension, clinically significant abnormalities)

- History of heart disease or current conduction system disease as indicated by QRS

duration > 0. 11

- Request for drug treatment

- Current parole or probation

- Pregnancy or current lactation

- Recent history of significant violent behavior

- Major current Axis I psychopathology (major depressive disorder, bipolar disorder,

suicide risk, schizophrenia)

- Current use of any prescription or over-the-counter medication

- Prior allergic or otherwise serious adverse reaction to quetiapine

Locations and Contacts

New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information

Starting date: August 2008
Last updated: February 4, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017